Shire plc Shire Plc : Elections For The Interim Dividend In Respect Of The Six Months To June 30, 2017

 
TIDMSHP 
 
 
   Elections for the interim dividend in respect of the six months to June 
30, 2017 
 
   September 11, 2017 - Shire plc (LSE: SHP, NASDAQ: SHPG) (the "Company") 
announced on August 3, 2017, an interim dividend of 5.09 US cents per 
Ordinary Share payable on October 20, 2017, to shareholders on the 
register of members at the close of business on September 8, 2017. 
 
   Holders of Ordinary Shares are notified that, in order to receive UK 
sourced dividends via the Company's Income Access Share arrangements 
("IAS Arrangements"), they need to have submitted a valid IAS 
Arrangements election form to the Company's Registrar, Equiniti, by no 
later than 5pm (BST) on September 22, 2017. 
 
   Holders of Ordinary Shares are advised that: 
 
 
   -- any previous elections made using versions of the IAS Arrangements 
      election form in use prior to February 16, 2016, and any elections deemed 
      to have been made prior to April 28, 2016, are no longer valid; and 
 
   -- if they do not elect, or have not elected using the newly formatted IAS 
      Arrangements election forms published on or after February 16, 2016, to 
      receive UK sourced dividends via the Company's IAS Arrangements, their 
      dividends will be Irish sourced and therefore incur Irish dividend 
      withholding tax, subject to applicable exemptions. 
 
 
   Internet links to the newly formatted IAS Arrangements election forms 
can be found at: 
http://investors.shire.com/shareholder-information/shareholder-forms.aspx 
 
 
   For further information concerning the IAS Arrangements, please contact 
Equiniti ([phone]). If you are in any doubt as to what 
action to take, please consult your tax advisor immediately. 
 
   Oliver Strawbridge 
 
   Senior Assistant Company Secretary 
 
   For further information please contact: 
 
 
 
 
Investor Relations 
Ian Karp             [e-mail]        [phone] 
Robert Coates        [e-mail]      [phone] 
Media 
Lisa Adler           [e-mail]   [phone] 
Debbi Ford           [e-mail]   [phone] 
 
 
   NOTES TO EDITORS 
 
   About Shire 
 
   Shire is the leading global biotechnology company focused on serving 
people with rare diseases. We strive to develop best-in-class products, 
many of which are available in more than 100 countries, across core 
therapeutic areas including Hematology, Immunology, Neuroscience, 
Ophthalmics, Lysosomal Storage Disorders, Gastrointestinal / Internal 
Medicine / Endocrine and Hereditary Angioedema; and a growing franchise 
in Oncology. 
 
   Our employees come to work every day with a shared mission: to develop 
and deliver breakthrough therapies for the hundreds of millions of 
people in the world affected by rare diseases and other high-need 
conditions, and who lack effective therapies to live their lives to the 
fullest. 
 
   www.shire.com 
 
   This announcement is distributed by Nasdaq Corporate Solutions on behalf 
of Nasdaq Corporate Solutions clients. 
 
   The issuer of this announcement warrants that they are solely 
responsible for the content, accuracy and originality of the information 
contained therein. 
 
   Source: Shire plc via Globenewswire 
 
 
 
 

(END) Dow Jones Newswires

September 11, 2017 07:00 ET (11:00 GMT)

Copyright (c) 2017 Dow Jones & Company, Inc.